Private Equity Backs Experimental Asthma Drug

MaRS tenant AIM Therapeutics Inc. has completed a $4 million round of private equity financing to advance testing of its lead compound for the treatment of asthma.

The experimental drug, known as AIM-002, is expected to move through preclinical toxicology, safety studies and formulation development by the end of 2008, before approval is sought for Phase II clinical studies.

AIM-002 is based on the company’s most advanced drug, Neutropel.  It is a non-toxic, non-steroidal anti-inflammatory that keeps airways clear and prevents asthma attacks.

Similar anti-inflammatory approaches may also apply to pancreatitis, arthritis, sepsis, Crohn’s disease, tissue damage and injury from cardiopulmonary bypass surgery.

AIM Therapeutics is a pharmaceutical company focused on the development of anti-inflammatory based medical treatments for asthma, cardiovascular disease, diabetes, spinal cord injury and other inflammatory and immune disorders. For more information visit www.aimtherapeutics.com.

• Email Page
• Print Page
• Increase Font
• Decrease Font

MaRS FACTS

MaRS provides advisory services to entrepreneurs – from market intelligence and financing, to partnership building, sales and PR advice – through its team of Venture Group advisors.